Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Response Study of Exenatide in Japanese Patients with Type 2 Diabetes
NCT00382239Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2006
- Primary completion
- May 2007
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of exenatide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by AstraZeneca. Primary endpoint: Change in HbA1c (glycosylated hemoglobin) at 12 weeks. Started Sep 2006; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00382239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00382239.